(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for ...
Many older adults with advanced cancer receive potentially aggressive treatment but not a lot of supportive care, according ...
Around 21 million adults in the U.S. (8.4%) experienced a major depressive episode in 2023 and Medicare Part B recipients are ...
Researchers analyzed 33,744 fee-for-service Medicare decedents with distant-stage breast, prostate, pancreatic, or lung cancers who died between 2014 and 2019.
Increasing numbers of women are getting additional screenings to rule out breast cancer. But such screenings cost money, out ...
Several key members of the Senate Finance Committee have reintroduced a bill that seeks to establish a Medicare coverage ...
Members of the Senate Finance Committee have reintroduced the Medicare Multi-Cancer Early Detection (MCED) Screening Coverage Act, a bipartisan bill that would establish a Medicare Coverage pathway to ...
Guardant Health (NYSE:GH) reported fourth-quarter adjusted EPS loss of 62 cents, compared to a loss of 64 cents a year ago, ...
In addition to the coverage in NSCLC, Signatera is also covered by Medicare for adjuvant and recurrence monitoring in colorectal cancer, muscle-invasive bladder cancer, breast cancer, and ovarian ...
Natera (NTRA) announced that its Signatera test has met coverage requirements from the Centers for Medicare & Medicaid Services’ Molecular ...
Many Medicare patients with advanced cancer receive potentially aggressive treatment at the expense of supportive care, according to a study that analyzed Medicare records. The study, published in ...